LKT Laboratories, Inc.

PF-04691502 Dihydrate

Phone: 888-558-5227
651-644-8424
Fax: 888-558-7329
Email: getinfo@lktlabs.com
Web: lktlabs.com

Product Information

Product ID P2002
CAS No.
Chemical Name
Synonym



Formula $C_{22}H_{27}N_5O_4 \cdot 2H_2O$
Formula Wt. 461.51
Melting Point
Purity ≥98%
Solubility

DMSO	14 mg/mL (32.9 mM)
Water	Insoluble
Ethanol	Insoluble

Store Temp -20°C
Ship Temp Ambient

Bulk quanitites available upon request

Product ID	Size
P2002	1 mg
P2002	5 mg
P2002	10 mg

Description PF-04691502 inhibits PI3K and mTORC1/2, exhibiting anticancer chemotherapeutic and anti-angiogenic activities. In nasopharyngeal carcinoma cells, PF-04691502 induces G0/G1 cell cycle arrest and apoptosis, inhibiting proliferation. In similar animal models, PF-04691502 decreases tumor volume and weight. Additionally, PF-04691502 decreases tumor growth of bladder cancer tumors in vivo and decreases VEGF secretion and cell proliferation in vitro.

References

Cirone P, Andresen CJ, Eswaraka JR, et al. Patient-derived xenografts reveal limits to PI3K/mTOR- and MEK-mediated inhibition of bladder cancer. Cancer Chemother Pharmacol. 2014 Mar;73(3):525-38. PMID: 24442130.

Wong CH, Loong HH, Hui CW, et al. Preclinical evaluation of the PI3K-mTOR dual inhibitor PF-04691502 as a novel therapeutic drug in nasopharyngeal carcinoma. Invest New Drugs. 2013 Dec;31(6):1399-408. PMID: 23975511.

Yuan J, Mehta PP, Yin MJ, et al. PF-04691502, a potent and selective oral inhibitor of PI3K and mTOR kinases with antitumor activity. Mol Cancer Ther. 2011 Nov;10(11):2189-99. PMID: 21750219.